Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 8c

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

November 7, 2018 7:00 AM EST

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2018.

This is a very exciting time for our company, said Dr. Sharon Mates, Chairman and CEO of ITCI. We are pleased with the progress we have made in numerous areas including the completion of our new drug application submission to the FDA for lumateperone for the treatment of schizophrenia, the completion of patient... More